Entrada Therapeutics (TRDA) H.C. Wainwright 26th Annual Global Investment Conference summary

Strategic and clinical program updates

• Workforce expanded from 20 to over 170, supporting a robust pipeline of intracellular therapeutics targeting severe diseases.

• Lead DMD program ENTR-601-44 showed strong safety and dose-dependent efficacy in a UK healthy volunteer study, with global patient trials planned to start in Q4.

• ENTR-601-44 and ENTR-601-45 will enter multi-ascending patient studies, transitioning to phase II-B, with ENTR-601-50 to follow early next year.

• Vertex partnership for myotonic dystrophy Type 1 is in phase I/II trials, with the SAD portion expected to complete by year-end and full study by 2026.

• Financial position is strong, with $470 million in cash and runway into early 2027.

Platform and technology insights

• Proprietary Endosomal Escape Vehicle (EEV) platform enables efficient intracellular delivery, achieving up to 50% endosomal escape versus 1–2% for traditional methods.

• EEVs are conjugated to various therapeutic agents, with tissue and target specificity optimized through extensive screening.

• The same EEV is used across DMD and DM1 programs, supporting platform scalability.

• EEV-decorated lipid nanoparticles demonstrated improved transfection, gene editing, and mRNA expression in preclinical studies.

Preclinical and clinical data highlights

• Animal models showed near-saturation of exon skipping and dystrophin restoration at low, clinically relevant doses, with durable effects and functional muscle improvement.

• Non-human primate studies revealed a strong correlation between drug concentration and target engagement, supporting clinical dose selection.

• Human volunteer trial demonstrated dose-dependent plasma and muscle concentrations, with high safety and tolerability at 6 mg/kg.

• No treatment-emergent events or significant lab changes observed; subchronic tox studies support potential for higher dosing.